In the adjuvant setting, the Impower010 trial of 1269 patients with resected NSCLC demonstrated that those patients randomized to adjuvant atezolizumab vs. best supportive care had superior DFS, particularly patients with PD-L1% > 1% [174]. Here, CD274 is linked to non-small cell lung carcinoma.